HUMAN ANTI RANIBIZUMAB (DRUG/TARGET COMPLEX)

Human Anti-Ranibizumab Antibody, clone AbD29928 specifically recognizes the Fab fragment antibody drug ranibizumab when in complex with its target, human vascular endothelial growth factor A (VEGF-A). The antibody does not recognize free ranibizumab or unbound recombinant human VEGF-A. It can be used to measure levels of ranibizumab and biosimilars in patient samples.Clone AbD29928 is a monovalent Fab format antibody that can be used to develop a pharmacokinetic (PK) antigen capture assay to measure free ranibizumab captured via immobilized VEGF-A.This antibody also recognizes bevacizumab when in complex with human VEGF-A.Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.View a summary of all anti-ranibizumab antibodies

• Clonality: Monoclonal
• Host: Human
• Isotype: HuCAL Fab monovalent

• Quantity: 0.1 mg
• Storage: +4ºC, -20ºC if preferred
• Buffer: Phosphate buffered saline, 0.01% Thiomersal

• ELISA (ELISA)